Publications by authors named "Brayden D Hamill"
Article Synopsis
- - Metastatic colorectal cancer (mCRC) significantly contributes to cancer-related deaths with current treatments only relieving symptoms and resulting in a low survival rate of around 11%.
- - T-cell factor (TCF) transcription plays a crucial role in mCRC by driving a process called epithelial-mesenchymal transition (EMT), leading to drug resistance and cancer spread.
- - Researchers have developed TOP2A ATP-competitive inhibitors that target TCF-transcription without causing DNA damage, representing a promising new treatment strategy for mCRC and potentially other cancers.
Recently, we characterized neoamphimedine (neo) as an ATP-competitive inhibitor of the ATPase domain of human Topoisomerase IIα. Thus far, neo is the only pyridoacridine with this mechanism of action. One limiting factor in the development of neo as a therapeutic agent has been access to sufficient amounts of material for biological testing.
View Article and Find Full Text PDF